To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered either as a continuous intravenous infusion or subcutaneous bolus once daily. To investigate possible ongoing coagulation by coagulation markers during antithrombotic therapy with standard doses of enoxaparin
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
39
Drug class: Low-molecular weight heparin
Tampere University Hospital
Tampere, Pirkanmaa, Finland
Helsinki University Central Hospital, Meilahti
Helsinki, Uusimaa, Finland
Plasma anti-factor Xa level
Change in plasma anti-factor Xa levels between baseline and 72 hours
Time frame: 72 hours
Incidence of Venous thromboembolism
If clinically suspected a compression ultrasound will be done
Time frame: 90 days
Incidence of Bleeding
Major and minor bleeding events will be reported
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.